New England Journal of Medicine
Browse Interactive Medical Case from the New England Journal of Medicine.
Browse Interactive Medical Case from the New England Journal of Medicine.
Subcutaneous administration of the monoclonal antibody L9LS protected adults against controlled Plasmodium falciparum infection in a phase 1 trial. Whether a monoclonal antibody administered subcut…
Review Article from The New England Journal of Medicine — Wearable Digital Health Technologies for Monitoring in Cardiovascular Medicine
Despite being absolutely clear that she wanted a quick, painless end of life, a geriatrician’s elderly mother receives aggressive care. How can we ensure that…
Recent approvals of exa-cel for treatment of sickle cell disease and transfusion-dependent β-thalassemia mark the dawn of the era of gene editing in medicine. But…
Exagamglogene autotemcel (exa-cel) is a nonviral cell therapy designed to reactivate fetal hemoglobin synthesis through ex vivo clustered regularly interspaced short palindromic repeats (CRISPR)–Ca…
Recent approvals of exa-cel for treatment of sickle cell disease and transfusion-dependent β-thalassemia mark the dawn of the era of gene editing in medicine. But…
A 47-year-old man presented with 2-day history of weakness and fever. Laboratory studies showed pancytopenia. A bone marrow biopsy showed promyelocytes with abundant intracellular rods.
Most moderate-to-late–preterm infants need nutritional support until they are feeding exclusively on their mother’s breast milk. Evidence to guide nutrition strategies for these infants is…
Chimeric antigen receptor (CAR) T-cell therapies have revolutionized the treatment landscape for patients with relapsed or refractory B-cell lymphoid cancers.1 With studies showing that more…
Recent approvals of exa-cel for treatment of sickle cell disease and transfusion-dependent β-thalassemia mark the dawn of the era of gene editing in medicine. But…